Literature DB >> 8036522

Localized scleroderma in childhood: a report of 30 cases.

Y Uziel1, B R Krafchik, E D Silverman, P S Thorner, R M Laxer.   

Abstract

Localized scleroderma (LS), a rare disease that occurs primarily in the pediatric age group, differs from systemic sclerosis (SSc) in that it is usually limited to the skin and subcutaneous tissue and is only rarely associated with systemic manifestations. The authors' experience with pediatric LS seen in 30 patients at a tertiary care center was reviewed: 26 had linear scleroderma, 19 on an extremity and 7 on the face; 3 had morphea; and 1 had generalized morphea. Antinuclear antibodies were present in 76% and rheumatoid factor in 39%. Five of 19 patients with linear scleroderma that involved an extremity had growth failure in that limb, and 1 required surgery. Sclerodermatous involvement over a joint resulted in limited range of movement in 6 patients, and 1 required surgery. One of the 30 patients developed SSc and polymyositis. There was difficulty in evaluating disease activity and hence in evaluating treatment. This experience with a large patient population suggests that LS, although usually a self-limiting disease, can result in significant morbidity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8036522     DOI: 10.1016/0049-0172(94)90028-0

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  11 in total

Review 1.  Systemic manifestations in localized scleroderma.

Authors:  Francesco Zulian
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

2.  Linear scleroderma in a child with diabetes.

Authors:  Rajiv Kuruppu Goonetilleke; Shona Coutts; Julie Edje
Journal:  BMJ Case Rep       Date:  2009-05-12

3.  Frequency of antinuclear antibodies in mestizo Mexican children with morphea.

Authors:  Elizabeth Guevara-Gutiérrez; Janeth Yinh-Lao; Patricia García-Gutiérrez; Alberto Tlacuilo-Parra
Journal:  Clin Rheumatol       Date:  2010-06-14       Impact factor: 2.980

Review 4.  Recognition and management of scleroderma in children.

Authors:  I Foeldvari; N Wulffraat
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 5.  Systemic and localized scleroderma in children: current and future treatment options.

Authors:  Margalit E Rosenkranz; Lucila M A Agle; Petros Efthimiou; Thomas J A Lehman
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 6.  Development of minimum standards of care for juvenile localized scleroderma.

Authors:  Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok
Journal:  Eur J Pediatr       Date:  2018-05-04       Impact factor: 3.183

7.  A rare case of juvenile localised scleroderma with intra-oral and dental involvement.

Authors:  Peng Wang; Wei Guo; Shutai Liu
Journal:  Exp Ther Med       Date:  2015-10-12       Impact factor: 2.447

8.  Correlates of self-reported quality of life in adults and children with morphea.

Authors:  Shinjita Das; Ira Bernstein; Heidi Jacobe
Journal:  J Am Acad Dermatol       Date:  2014-02-16       Impact factor: 11.527

9.  Clinical Usefulness of Magnetic Resonance Imaging in Four Children With Scleroderma.

Authors:  Kazushi Agata; Hisashi Kawashima; Atsushi Kumada; Yasuyo Kashiwagi; Hiroko Hara
Journal:  Arch Rheumatol       Date:  2017-11-02       Impact factor: 1.472

10.  Increased serum levels of TGFbeta1 in children with localized scleroderma.

Authors:  Yosef Uziel; Brian M Feldman; Bernice R Krafchik; Ronald M Laxer; Rae Sm Yeung
Journal:  Pediatr Rheumatol Online J       Date:  2007-12-03       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.